T-cell priming in bone marrow: the potential for long-lasting protective anti-tumor immunity.
about
Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of ImmunotherapyMarrow-Infiltrating Lymphocytes - Role in Biology and Cancer TherapyCerebral ischemia increases bone marrow CD4+CD25+FoxP3+ regulatory T cells in mice via signals from sympathetic nervous systemTumor specific regulatory T cells in the bone marrow of breast cancer patients selectively upregulate the emigration receptor S1P1.Modified vaccinia virus Ankara exerts potent immune modulatory activities in a murine modelLocalized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis.CXCR4 expression on pathogenic T cells facilitates their bone marrow infiltration in a mouse model of aplastic anemiaT cell-expressed CD40L potentiates the bone anabolic activity of intermittent PTH treatment.Bone marrow and the control of immunity.Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial.A randomized phase II study of radiation induced immune boost in operable non-small cell lung cancer (RadImmune trial).Significance of heparanase in cancer and inflammation.Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing.T cell-mediated immunotherapy of metastases: state of the art in 2005.IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity.Vaccine-based approaches to squamous cell carcinoma of the head and neck.Secondary lymphoid organs contribute to, but are not required for the induction of graft-versus-host responses following allogeneic bone marrow transplantation: a shifting paradigm for T cell allo-activationBone marrow microenvironment in cancer patients: immunological aspects and clinical implications.Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function.Adoptive immunotherapy of metastatic breast cancer: present and future.Adoptive Cell Therapy in Multiple Myeloma.Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus.Antitumor T cell responses in bladder cancer are directed against a limited set of antigens and are modulated by regulatory T cells and routine treatment approaches.Functional TLR9 modulates bone marrow B cells from rheumatoid arthritis patients.Long-term survival after adoptive bone marrow T cell therapy of advanced metastasized breast cancer: follow-up analysis of a clinical pilot trial.Subtle CD20 positivity in the bone marrow of a patient who has a mucosa-associated lymphoid tissue lymphoma should not be regarded as evidence of involvement in the bone marrow.
P2860
Q26745444-0B2A88FF-0408-4D4B-B8E2-79D350F56863Q26749560-6E26B660-0EDF-43CC-93C3-4456861387F7Q28245649-B9339ADA-762A-4091-8B12-0C0CD9FBFB79Q33607086-61C3EDD9-91BD-4C42-803B-55FD18218D2AQ33632203-77412F7B-B977-4555-B02E-6E7A7F28DB30Q33933665-35A72245-A643-48F7-989D-8C87430EAF94Q35056748-C00353B9-1D2F-4DB1-B6A9-CEA3F5210E93Q35220648-276FC81A-D131-4ED2-BB37-1D6C5816E7AAQ35224501-6A617F0B-4689-41B8-8DD2-A6D06655EB95Q35653129-29555D98-DFEE-4ED4-ADCE-2B4C4EF8729FQ35798947-0C12972D-B61F-481F-BCA0-1C6BB53B4DE0Q35873571-4913EDC8-FCD7-459D-9010-CE5176B83A74Q36101233-E6F4B2E8-13DE-444C-B703-77D26694E375Q36117230-85C8F8FE-3517-4C52-A982-3E14D153C151Q36210864-FE14E8AA-BC69-4A89-97FE-10EA93D0A30FQ36384826-3BDCE4E4-74F8-49E3-938E-D1414BB945D7Q36714541-D4568BB4-F45D-4E39-A378-4F1EBAF7508CQ37338471-580EBA9D-6D02-497E-95AB-1AB049C43990Q38053396-0EFCB868-45B7-4B56-A024-8C7B4F6E4072Q38161930-988CB63E-D7D7-4F6F-86A8-E55655C387AAQ38171325-034E1A5F-DE52-4A2B-B8EC-2E45D52F1531Q38635138-341991B7-7369-4C6E-A77F-C9E905F907CFQ40479713-A9E83388-9637-4352-B444-D9DBEACBEBC4Q43498496-68E8BF43-B417-439E-B0BD-9D864494C95AQ46522981-2E53824C-82BB-4A8C-B170-C58A6081E1ACQ50904556-E48331E4-9128-4487-BA2B-0324A8379BC6Q53133469-F59F3AEE-0A04-48A0-BF5C-6D6803A68EE9
P2860
T-cell priming in bone marrow: the potential for long-lasting protective anti-tumor immunity.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
T-cell priming in bone marrow: ...... rotective anti-tumor immunity.
@ast
T-cell priming in bone marrow: ...... rotective anti-tumor immunity.
@en
type
label
T-cell priming in bone marrow: ...... rotective anti-tumor immunity.
@ast
T-cell priming in bone marrow: ...... rotective anti-tumor immunity.
@en
prefLabel
T-cell priming in bone marrow: ...... rotective anti-tumor immunity.
@ast
T-cell priming in bone marrow: ...... rotective anti-tumor immunity.
@en
P2093
P1476
T-cell priming in bone marrow: ...... rotective anti-tumor immunity.
@en
P2093
Markus Feuerer
Philipp Beckhove
Philippe Fournier
Thorsten Ahlert
Viktor Umansky
Volker Schirrmacher
P304
P356
10.1016/J.MOLMED.2003.10.001
P577
2003-12-01T00:00:00Z